Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 79.55 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $9.000 thousand which missed the analyst consensus estimate of $5.300 million by 99.83 percent. This is a 99.40 percent decrease over sales of $1.505 million the same period last year.